CAPOX Regimen for Metastatic Sigmoid Colon Cancer
For a chemotherapy-naïve patient with metastatic sigmoid colon cancer, CAPOX (capecitabine plus oxaliplatin) is a well-established first-line treatment option that has demonstrated non-inferiority to FOLFOX with similar efficacy and a more convenient administration schedule.
Standard CAPOX Dosing Regimen
The recommended dosing schedule based on FDA labeling and international guidelines 1:
- Oxaliplatin: 130 mg/m² IV infusion over 2 hours on Day 1
- Capecitabine: 1,000 mg/m² orally twice daily on Days 1-14
- Cycle length: Every 21 days (3-week cycles)
- Duration: Continue until disease progression or unacceptable toxicity
Important North American Dosing Consideration
The capecitabine dose of 1,000 mg/m² twice daily is specifically recommended for North American patients 2, 3, 4. European studies used 1,250 mg/m² twice daily, but evidence suggests North American patients experience greater toxicity with fluoropyrimidines and require lower starting doses 2, 3. The 1,000 mg/m² dose provides similar efficacy with improved tolerability.
Evidence Supporting CAPOX
CAPOX has been validated as equivalent to FOLFOX in a large randomized phase III trial of 2,034 patients, showing similar median PFS (8.0 vs 8.5 months) and establishing non-inferiority 3. Multiple guidelines confirm CAPOX as an alternative to infusional 5-FU/oxaliplatin combinations with similar activity and safety 5, 6, 7, 8, 9.
Addition of Bevacizumab
Consider adding bevacizumab 7.5 mg/kg IV on Day 1 of each cycle 10. The combination of CAPOX plus bevacizumab is supported by:
- Level I, Grade A evidence for improved outcomes 5, 8
- FDA approval for first-line metastatic colorectal cancer 10
- Demonstrated improvements in PFS when bevacizumab added to CAPOX (though more modest than with other regimens) 10
Critical bevacizumab precautions:
- Increased arterial thrombotic events, especially in patients ≥65 years
- Requires 6-week interval before elective surgery and 6-8 weeks post-operatively before restarting
- Contraindicated with wound healing issues
Oxaliplatin Management Strategy
Plan for oxaliplatin discontinuation after 3-4 months (or 6 cycles) to prevent cumulative neurotoxicity 2, 3, 1:
- Continue capecitabine ± bevacizumab as maintenance therapy
- Discontinue oxaliplatin earlier if ≥Grade 2 neuropathy develops
- Can reintroduce oxaliplatin if discontinued for neurotoxicity (not progression) and symptoms resolve
This stop-and-go approach maintains disease control while minimizing long-term neurological sequelae 3.
Dose Modifications for Toxicity
Per FDA labeling 1:
Peripheral neuropathy:
- Persistent Grade 2: Reduce oxaliplatin to 75 mg/m²
- Persistent Grade 3: Consider discontinuing oxaliplatin
- Grade 4: Permanently discontinue oxaliplatin
Myelosuppression (Grade 3-4 neutropenia or thrombocytopenia):
- Delay next cycle until ANC ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L
- Reduce oxaliplatin to 75 mg/m²
Gastrointestinal toxicity (Grade 3-4):
- After recovery, reduce oxaliplatin to 75 mg/m²
Alternative Considerations
If patient cannot tolerate oxaliplatin or has contraindications:
- FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab is equally effective 3, 9
- For frail patients: Consider fluoropyrimidine monotherapy ± bevacizumab 3, 9
For RAS wild-type, left-sided tumors: Anti-EGFR antibodies (cetuximab or panitumumab) can be combined with FOLFOX or FOLFIRI, though not with bevacizumab 9, 10.
For aggressive disease requiring maximum response (e.g., potentially resectable metastases): Consider FOLFOXIRI ± bevacizumab in fit patients with good performance status 9, 10.
Monitoring Requirements
- CT imaging every 2 months to assess for conversion to resectability 11
- Monitor for hand-foot syndrome (occurs in ~31% with capecitabine) 3
- Assess for neurotoxicity before each cycle
- CBC before each cycle
Common Pitfalls to Avoid
- Do not use calcium/magnesium infusions to prevent oxaliplatin neuropathy—proven ineffective 3
- Do not combine bevacizumab with anti-EGFR antibodies—increases toxicity without benefit 2, 8, 9
- Do not continue oxaliplatin beyond 6 months in responding patients—cumulative neurotoxicity outweighs benefit
- Monitor closely during first cycle for capecitabine toxicity and adjust dose as needed 2, 4